SUPN

#1830
Supernus Pharmaceuticals, Inc. - Common Stock
43.9 4 USD
0.00%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
43.71
43.96
Intervallo Annuale
42.45
59.68
Variazione giornaliera
+0.46%
Variazione Mensile
-12.90%
Variazione di 6 mesi
-19.03%
Variazione Annuale
-18.63%
Chiusura Precedente
43.7 4
Open
43.8 5
Minimo
43.7 1
Massimo
43.9 6
Volume
57
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K

SUPERNUS PHARMACEUTICALS, INC. current report, 21 June 2023

Full document

Business Context and Reporting Period

This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on June 21, 2023. The filing discloses the entry into a Material Definitive Agreement regarding the settlement of patent litigation involving the Company's product, Oxtellar XR (oxcarbazepine) extended-release tablets.

Key Financial Metrics

The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on a legal settlement and licensing agreement.

Material Changes and Agreements

  • Settlement of Litigation: Supernus entered into Settlement and License Agreements with Apotex Inc. and Apotex Corp. to resolve ongoing patent litigation concerning Apotex's Abbreviated New Drug Application (ANDA) for a generic version of Oxtellar XR.
  • Patents Involved: The settlement covers ten specific United States Patents (Nos. 7,722,898; 7,910,131; 8,617,600; 8,821,930; 9,119,791; 9,351,975; 9,370,525; 9,855,278; 10,220,042; and 11,166,960).
  • Dismissal of Claims: Both parties agreed to dismiss all claims, counter-claims, and defenses in the ongoing litigation.
  • Licensing Terms: Supernus granted Apotex a license to market a generic version of Oxtellar XR in the United States beginning on September 1, 2024, or earlier under certain circumstances.
  • Authorized Generic Rights: Supernus retained the right to market an authorized generic product itself, through an affiliate, or through a third party.

Guidance, Outlook, and Risks

The filing does not contain updated financial guidance, management commentary on future performance, or a discussion of general risks. The primary contingency addressed is the resolution of the patent dispute, which establishes a definitive timeline for generic market entry by Apotex while preserving Supernus's ability to compete with an authorized generic.

Key Facts for Investor Verification

  • Verify the exact terms regarding the "earlier" market entry date for Apotex's generic product mentioned in the agreement.
  • Confirm the strategic plan and timeline for Supernus's own authorized generic product launch.
  • Assess the potential revenue impact of generic competition entering the market on September 1, 2024.
  • Review the specific patents settled to ensure no other pending litigation remains regarding Oxtellar XR.

Notizie